Literature DB >> 15156184

Role of the TEL-AML1 fusion gene in the molecular pathogenesis of childhood acute lymphoblastic leukaemia.

Arthur Zelent1, Mel Greaves, Tariq Enver.   

Abstract

Balanced chromosomal translocations are frequently associated with haematopoietic neoplasms and often involve genes that encode transcription factors, which play critical roles in normal haematopoiesis. Fusion oncoproteins that arise from chimeric genes generated by such translocations are usually stable and consistent molecular markers for a given disease subtype and contribute to the leukaemogenic processes. The t(12;21)(p13;q22) chromosomal translocation is the most frequent illegitimate gene recombination in paediatric cancer, occurring in approximately 25% of common (c) B-cell precursor acute lymphoblastic leukaemia (cALL) cases. The rearrangement results in the in-frame fusion of the 5' region of the ETS-related gene, TEL (ETV6), to almost the entire AML1 (RUNX1) locus and is associated with favourable prognosis following conventional therapeutic strategies. We discuss here the prenatal origins of the TEL/AML1 translocation as an initiating mutation, the role of TEL-AML1 in cellular transformation and the molecular mechanisms by which the chimeric protein imposes altered patterns of gene expression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15156184     DOI: 10.1038/sj.onc.1207672

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  43 in total

1.  Folylpolyglutamate synthetase gene transcription is regulated by a multiprotein complex that binds the TEL-AML1 fusion in acute lymphoblastic leukemia.

Authors:  Guy J Leclerc; Christopher Sanderson; Stephen Hunger; Meenakshi Devidas; Julio C Barredo
Journal:  Leuk Res       Date:  2010-06-09       Impact factor: 3.156

Review 2.  DNA microarrays in the diagnosis and management of acute lymphoblastic leukemia.

Authors:  Adolfo A Ferrando; A Thomas Look
Journal:  Int J Hematol       Date:  2004-12       Impact factor: 2.490

Review 3.  Molecular mechanisms of ETS transcription factor-mediated tumorigenesis.

Authors:  Adwitiya Kar; Arthur Gutierrez-Hartmann
Journal:  Crit Rev Biochem Mol Biol       Date:  2013-09-25       Impact factor: 8.250

4.  Fusion transcripts and transcribed retrotransposed loci discovered through comprehensive transcriptome analysis using Paired-End diTags (PETs).

Authors:  Yijun Ruan; Hong Sain Ooi; Siew Woh Choo; Kuo Ping Chiu; Xiao Dong Zhao; K G Srinivasan; Fei Yao; Chiou Yu Choo; Jun Liu; Pramila Ariyaratne; Wilson G W Bin; Vladimir A Kuznetsov; Atif Shahab; Wing-Kin Sung; Guillaume Bourque; Nallasivam Palanisamy; Chia-Lin Wei
Journal:  Genome Res       Date:  2007-06       Impact factor: 9.043

Review 5.  Posttranslational modifications of RUNX1 as potential anticancer targets.

Authors:  S Goyama; G Huang; M Kurokawa; J C Mulloy
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

Review 6.  Role of RUNX1 in hematological malignancies.

Authors:  Raman Sood; Yasuhiko Kamikubo; Paul Liu
Journal:  Blood       Date:  2017-02-08       Impact factor: 22.113

7.  Tyrosyl phosphorylation toggles a Runx1 switch.

Authors:  Benjamin G Neel; Nancy A Speck
Journal:  Genes Dev       Date:  2012-07-15       Impact factor: 11.361

8.  Maternal iAMP21 acute lymphoblastic leukemia detected on prenatal cell-free DNA genetic screening.

Authors:  Marlise R Luskin; Marie N Discenza; Sarah Rae Easter; Paola Dal Cin; Renius Owen; Bernard Ilagan; Meredith Masiello; Andrew A Lane
Journal:  Blood Adv       Date:  2017-08-15

9.  The TEL-AML1 fusion protein of acute lymphoblastic leukemia modulates IRF3 activity during early B-cell differentiation.

Authors:  A de Laurentiis; J Hiscott; M Alcalay
Journal:  Oncogene       Date:  2015-04-20       Impact factor: 9.867

10.  Chromosome 12p deletions in TEL-AML1 childhood acute lymphoblastic leukemia are associated with retrotransposon elements and occur postnatally.

Authors:  Joseph L Wiemels; Jerry Hofmann; Michelle Kang; Rebecca Selzer; Roland Green; Mi Zhou; Sheng Zhong; Luoping Zhang; Martyn T Smith; Carmen Marsit; Mignon Loh; Patricia Buffler; Ru-Fang Yeh
Journal:  Cancer Res       Date:  2008-12-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.